In a nutshell This study examined whether the duration of primary (first round) hormone therapy impacts abiraterone (Zytiga) treatment for metastatic castration-resistant prostate cancer (mCRPC). Researchers concluded that the benefits of abiraterone were not dependent on the duration of primary hormone therapy. Some background Androgen...
Read MoreTreatment(s) already received-Hormonal therapy Posts on Medivizor
Long-term hormone therapy and cognitive function
In a nutshell This study examined the effects of androgen deprivation therapy (ADT) on cognitive function over 3 years. Researchers reported no significant differences in cognitive function following long-term ADT compared to control participants not undergoing ADT. Some background ADT is a type of hormone therapy commonly used to treat prostate...
Read MoreSecondary hormone therapy with enzalutamide also effective for metastatic prostate cancer affecting the lung or liver
In a nutshell This study examined the effects of enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer (mCRPC) that has spread to the lungs and/or liver. Researchers reported that enzalutamide is safe and effective for men with mCRPC affecting the lung or liver. Some background When prostate cancer spreads outside of...
Read MoreAdding docetaxel-based chemotherapy early to hormone therapy can improve survival
In a nutshell This study examined the benefit of adding chemotherapy to androgen deprivation therapy (ADT) early to treat metastatic hormone-sensitive prostate cancer. Researchers reported a survival benefit when chemotherapy was added to ADT. This benefit was only detected with chemotherapy involving docetaxel (Taxotere). Some background ADT is a...
Read MoreThe effects of antidepressants (SSRIs) on breast cancer survival prospects
In a nutshell This study investigated whether selective serotonin reuptake inhibitors (SSRIs) taken with tamoxifen (Nolvadex) influenced survival rates in breast cancer patients. The study also looked at the association between SSRI use and patients’ ability to stay on their oral hormone therapy drugs. Using SSRIs with tamoxifen had no effect...
Read MoreHormone therapy may shorten survival in African American men with low- or intermediate-risk prostate cancer
In a nutshell This study examined the effect of ethnicity on health outcomes with androgen deprivation therapy (ADT). Researchers reported shorter survival among African American men receiving ADT for low- or intermediate-risk prostate cancer compared to men of other ethnicities. Some background ADT is a type of hormone therapy used to treat...
Read MoreWhat treatments are available for patients progressing after primary and secondary hormone therapy?
In a nutshell This study examined treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) progressing after treatment with abiraterone acetate (Zytiga). Chemotherapy with docetaxel (Taxotere) was the most common subsequent therapy. Authors concluded that patients with mCRPC who progress after AA may still benefit from subsequent...
Read MoreHormone therapy associated with increased risk of depression
In a nutshell This study examined the effect of androgen deprivation therapy (ADT) on clinical depression. Authors reported that ADT increased the risk of depression and the need for psychiatric treatment. The risk of depression increased with duration of ADT. Some background ADT is a type of hormone therapy commonly used to treat prostate cancer....
Read MoreDecline in circulating tumor cells during treatment associated with better survival
In a nutshell This study examined the link between circulating tumor cells (CTCs) and treatment outcome in metastatic castration-resistant prostate cancer (mCRPC). Authors reported better survival outcomes for mCRPC patients with a significant decline in CTC count during treatment. Some background Metastatic castration-resistant prostate...
Read MorePotential predictor of treatment outcomes for metastatic castration-resistant prostate cancer
In a nutshell This study analyzed predictors of treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC). Researchers concluded that testosterone levels before treatment can help predict overall survival in men with mCRPC. Some background Hormone therapy is the standard of care for advanced prostate cancer, including...
Read MorePlatinum-based drugs: A possible strategy when other treatments stop working
In a nutshell This review analyzed platinum-based drugs in the treatment of advanced castration-resistant prostate cancer. While platinum-based drugs were often associated with various side effects, researchers reported moderate to good treatment effectivity in managing advanced prostate cancer. Some background Hormone therapy is the standard...
Read MoreCan tamoxifen reduce the risk of cancer-related mortality?
In a nutshell The authors aimed to determine whether long-term adjuvant (treatment given after the primary treatment) tamoxifen (Nolvadex) can reduce the risk of death by cancer in pre-menopausal women with estrogen-receptor positive (ER+) breast cancer. Long-term adjuvant tamoxifen treatment showed a reduction in the risk of death due to breast...
Read More
